Seven Eight Capital, LP Intercept Pharmaceuticals, Inc. Transaction History

Seven Eight Capital, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 06, 2020	SELL	$46.7 - $92.04 $331,570 - $653,484	-7,100 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$48.35 - $118.68 $343,285 - $842,628	7,100 New	7,100 $447,000
Q4 2018 Feb 14, 2019	SELL	$85.79 - $126.46 $404,843 - $596,764	-4,719 Closed	0 $0
Q3 2018 Oct 18, 2018	BUY	$88.49 - $127.55 $417,584 - $601,908	4,719 New	4,719 $596,000
Q1 2018 May 14, 2018	SELL	$52.72 - $67.25 $335,457 - $427,911	-6,363 Closed	0 $0
Q4 2017 Feb 12, 2018	SELL	$58.2 - $72.76 $4.89 Million - $6.11 Million	-84,024 Reduced 92.96%	6,363 $372,000
Q3 2017 Oct 16, 2017	BUY	$57.01 - $118.75 $5.15 Million - $10.7 Million	90,387	90,387 $5.25 Million

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.